Bacteria in Frogs and Reptiles Outsmart Animal Cancer Treatments

Researchers have discovered that a bacterium found in frogs and reptiles demonstrates greater effectiveness in eradicating tumors in animals compared to conventional cancer treatments, raising hopes for innovative approaches to oncology.

New Avenues in Cancer Research: Lessons from the Animal World

In the constant quest for more effective and less invasive cancer treatments, researchers are increasingly turning their attention to nature’s lesser-known resources. A recent breakthrough led by Professor Eijiro Miyako and his team at the Japan Advanced Institute of Science and Technology (JAIST) exemplifies this shift. The group set aside conventional laboratory settings and instead delved into the microbiome of wild creatures, hypothesizing that certain animals might host microbial allies capable of fighting cancer.

A Bacterial Discovery in Japanese Amphibians

Their journey began not with humans, but with Japanese tree frogs, fire-bellied newts, and green lizards. After isolating forty-five different strains from the intestinal tracts of these animals, attention quickly focused on one: Ewingella americana, identified in the gut of the frog species Dryophytes japonicus. This unmodified, naturally occurring bacterium would soon prove astonishingly potent in laboratory tests.

Unprecedented Results Against Colorectal Tumors

Perhaps the most remarkable part of this research emerged when Ewingella americana was injected into mice with colorectal tumors. The outcome defied expectations—tumors vanished completely in every treated animal. Standard therapies like doxorubicin or anti-PD-L1 antibodies rarely yield such uniform results. The implications for future cancer therapies are clear: natural bacterial agents might one day rival or even surpass existing treatments.

How Does Ewingella americana Work?

Several factors explain this extraordinary efficacy:

• Directly destroys cancer cells in tumors’ low-oxygen environments.
• Mobilizes a powerful immune response—triggering T-cells, B-cells, neutrophils, and a surge of cytokines such as TNF-α and IFN-γ.

Within just twenty-four hours of administration, bacterial concentrations soared inside the tumors, accelerating cell death.

A Cautious Path Forward

Admittedly, introducing live bacteria into oncology raises justified questions about safety. However, reassuring results were observed: after injection, Ewingella americana cleared rapidly from the bloodstream and showed no tendency to invade healthy organs such as the liver or kidneys. Any inflammation remained mild and transient; notably, chronic toxicity was absent after two months. While these findings remain within animal models for now, they hint at new directions for less invasive—and perhaps more precise—cancer therapies. Once again, nature’s ingenuity suggests there is still much to learn in our battle against cancer.